Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (DBCOND0152726)

Identifiers

Synonyms
Hormone Sensitive Metastatic Prostate Cancer / Metastatic Hormone Sensitive Prostate Cancer / Metastatic Hormone-sensitive Prostate Cancer

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Abiraterone
An antiandrogen used in the treatment of metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer.
Apalutamide
An androgen receptor inhibitor used to treat non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer.
Darolutamide
An androgen receptor antagonist used for castration-resistant, non-metastatic prostate cancer and metastatic hormone-sensitive prostate cancer.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT06661122
A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate CancerNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT06010914
A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate CancerNo drug interventionsNot AvailableNot Availablerecruiting
NCT06312670
Combining EPI-7386 with Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancertreatment2recruiting
NCT06392841
Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterationstreatment2not_yet_recruiting
NCT05676203
A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patientstreatment3recruiting
NCT03903835
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancertreatment3recruiting
NCT06019676
Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer PatientsNo drug interventionsNot AvailableNot Availablerecruiting
NCT03899467
The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPCtreatment2completed
NCT05649943
Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local TreatmenttreatmentNot Availablerecruiting
NCT05683964
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expressiondiagnostic0recruiting
NCT06479187
PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancerdiagnostic4not_yet_recruiting
NCT05956639
Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPCtreatment3recruiting
NCT05461261
The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancertreatment2recruiting
NCT04076059
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)treatment3active_not_recruiting
NCT02677896
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)treatment3completed
NCT05059236
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.treatment2active_not_recruiting
NCT06334120
An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in KoreaNot AvailableNot Availablerecruiting
NCT05901649
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or EnzalutamideNot AvailableNot Availablerecruiting
NCT06498921
An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical CareNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT02799602
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancertreatment3completed
NCT03343977
Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)treatment1 / 2withdrawn
NCT05381311
Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) StudyNo drug interventionsNot AvailableNot Availablecompleted
NCT00309985
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancertreatment3active_not_recruiting
NCT03532217
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancertreatment1completed
NCT04934722
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extensiontreatment3active_not_recruiting
NCT06452212
Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer PatientsNo drug interventionsNot AvailableNot Availablecompleted
NCT06134271
Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancertreatment2not_yet_recruiting
NCT04191096
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)treatment3active_not_recruiting
NCT03879122
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancertreatment2 / 3active_not_recruiting